McHugh Ann, El-Khuffash Afif, Franklin Orla, Breathnach Fionnuala M
Department of Obstetrics and Gynaecology, Royal College of Surgeons in Ireland, Rotunda Hospital, Dublin, Ireland.
Department of Neonatology, Royal College of Surgeons in Ireland, Rotunda Hospital, Dublin, Ireland.
Eur J Obstet Gynecol Reprod Biol. 2021 Mar;258:93-97. doi: 10.1016/j.ejogrb.2020.12.054. Epub 2020 Dec 31.
Maternal hyperoxygenation has been investigated as a potential diagnostic and therapeutic tool since the 1960s. Since then, it has been applied in many obstetric scenarios, both clinically and in the research setting. It is often administered without any determination of pre-hyperoxygenation maternal or fetal oxygen levels. Studies focussing on maternal oxygen therapy for the treatment of fetal growth restriction have been ongoing for over thirty years and there remains no clear evidence of benefit. Studies investigating the potential diagnostic or therapeutic role of maternal oxygen therapy in the setting of fetal congenital cardiac disease have reported varying success rates and some potentially worrying adverse effects. The purpose of this article is to review the effects of maternal hyperoxygenation on fetal and maternal health and to ascertain the safety of undertaking further clinical trials that employ the use of hyperoxygenation in pregnancy.
自20世纪60年代以来，母体高氧治疗一直作为一种潜在的诊断和治疗工具进行研究。从那时起，它已在许多产科场景中得到临床和研究应用。其施用通常没有对高氧治疗前的母体或胎儿氧水平进行任何测定。专注于母体氧疗治疗胎儿生长受限的研究已经进行了三十多年，但仍没有明确的获益证据。调查母体氧疗在胎儿先天性心脏病情况下潜在诊断或治疗作用的研究报告了不同的成功率以及一些潜在令人担忧的不良反应。本文的目的是综述母体高氧治疗对胎儿和母体健康的影响，并确定在妊娠中采用高氧治疗进行进一步临床试验的安全性。
